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Abstract
Genetic variants at three quantitative trait loci (QTL) for fetal haemoglobin (HbF), BCL11A,
HBS1L-MYB and the β-globin gene cluster, have attracted interest as potential targets of
therapeutic strategies for HbF reactivation in sickle cell anaemia (SCA). We carried out the
first systematic evaluation of critical single nucleotide polymorphisms at these disease modi-
fier loci in Nigerian patients with SCA. Common variants for BCL11A and HBS1L-MYB were
strongly associated with HbF levels. At both loci, secondary association signals were
detected, illustrating the mapping resolution attainable in this population. For BCL11A, the
two independent sites of association were represented by rs1427407 (primary site, p = 7.0 x
10−10) and rs6545816 (secondary site, conditioned on rs1427407: p = 0.02) and for HBS1L-
MYB by rs9402686 (HMIP-2B, p = 1.23 x 10−4) and rs66650371 (HMIP-2A, p = 0.002). Hap-
lotype analysis revealed similarities in the genetic architecture of BCL11A and HBS1L-MYB
in Nigerian patients. Variants at both loci also alleviated anaemia. The variant allele for the γ
globin gene promoter polymorphism XmnI-HBG2 was too infrequent in our patients to be
evaluated in this relatively small study. Studying the large and diverse SCA patient popula-
tions in African countries such as Nigeria will be key for a clearer understanding of how
these loci work and for the discovery of new disease modifier genes.
Introduction
Sickle cell anaemia (SCA), though a monogenic disorder, is highly clinically-diverse. Part of
this diversity derives from the variable genetic background of patients, and several of the fac-
tors underlying this have been identified [1]. Significant genetic disease modifiers are a co-
inheritance of α-thalassemia (the α-3.7 globin gene deletion) [2] and the presence of fetal-hae-
moglobin (HbF) inducing genotypes at the three major quantitative-trait loci (QTL) for HbF
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persistence [3–8]: XmnI-HBG2, BCL11A and HMIP. Co-inheritance of α-thalassemia is associ-
ated with reduced haemolytic events in sickle cell patients, due to decreased intracellular con-
centrations of the defective haemoglobin (HbS) and thus a decreased likelihood of HbS
polymerisation. Elevated levels of HbF are associated with increased life expectancy, reduced
incidence of painful crisis and fewer leg ulcers [9–11]. Accordingly, the three HbF QTL have
been shown to affect measures of disease pathology and severity [12–18].
Findings from genetic studies can provide guidance for new therapeutic approaches [19,
20]. Studying the large number of SCA patients residing in African countries such as Nigeria,
the country with the largest SCA patient population world-wide, promises not only the discov-
ery of new SCA modifier genes and therapeutic targets. It will also provide a better under-
standing of the known loci, their biological function and clinical significance. Here we are
presenting the first systematic evaluation of the known HbF modifier loci in a Nigerian SCA
patient population. Our data, obtained from 260 patients, give an initial estimate of the preva-
lence of critical HbF modifier variants at the three QTL and of their genetic architecture in
Nigerian patients, providing a starting point for subsequent large-scale population-genetic
studies.
Patients and methods
260 SCA patients (138 male, 122 female) were recruited from paediatric and adult sickle cell
clinics of Lagos University Teaching Hospital between March and October 2015, with a median
age of 13 years (range 5–46). Patients were excluded if they were younger than 5 years, of Hb SC
genotype, admitted to hospital, treated with hydroxyurea or had blood transfusion three months
prior to the study. The diagnosis was confirmed in all patients using high performance liquid
chromatography (Bio-Rad D-10; Bio-Rad Laboratories, Hercules, CA, USA). This method can-
not distinguish between Hb SS and Hb S/β0 genotypes. Since the two are phenotypically very
similar, the fact that a few patients must have the latter genotype can be disregarded.
The study protocol was approved by the Health Research Ethics Committee of Lagos
University Teaching Hospital (ADM/DCST/HREC/1686). Written informed consent was
obtained from the patients and parents/guardians prior to study enrolment. Children who
were seven years old gave assent to participate in the study. A study proforma was com-
pleted to obtain the socio-demographic and clinical data for all the study participants. A total
of 7 ml blood sample was taken from each patient for haematological, biochemical and geno-
typing assays. The full blood count (data summarised in S1 Table) was determined using an
automated haematology analyser (Mindray, BC-2800).
DNA was extracted using the phenol-chloroform method. Seven single nucleotide poly-
morphisms tagging trait-relevant genetic variability at the three HbF modifier loci (BCL11A,
HBS1L-MYB, and XmnI-HBG2) were genotyped. rs6545816 and rs1427407 of BCL11A and
rs9376090, rs66650371, rs9402686 and rs6920211 of HMIP-2 were assayed using TaqMan
chemistry, as previously described [21]. The assay for XmnI-HBG2 (rs7482144) was performed
after PCR-amplification specifically of HBG2 promoter sequence, omitting the homologous
HBG1 area [22]. Genotypes for all markers were in Hardy-Weinberg equilibrium, except
rs7482144, which is in linkage with the sickle mutation.
Genetic association analysis was performed by multiple regression, with age and sex as
covariates (SPSS v. 15). Blood counts data were log-transformed to normalize them. Haplo-
types were constructed from the patient genotypes with Haploview 4.2 [23].
1000 Genomes project, Phase III, data [24] were accessed at http://phase3browser.
1000genomes.org. Phase-aligned variant call format (vcf) files were downloaded, covering
chromosome 2 from position (hg19) 60,710,000 to 60,730,000.
Genetics of fetal haemoglobin in sickle cell anaemia in Nigeria
PLOS ONE | https://doi.org/10.1371/journal.pone.0197927 June 7, 2018 2 / 10
CRC 2014/07). SM and SLT: FP7, European
Commission (Thalamoss). SM and SLT: Shire UK
plc (Collaborative Grant).
Competing interests: SM and SLT have received a
Collaborative Grant from Shire UK plc. This does
not alter our adherence to PLOS ONE policies on
sharing data and materials.
Results
Seven key genetic variants, rs6545816 and rs1427407 (BCL11A), rs9376090, rs66650371,
rs9402686 and rs6920211 (HBS1L-MYB) and rs7482144 (XmnI-HBG2) were genotyped in 260
Nigerian SCA patients (summary data shown in Table 1) and their effects on HbF levels and
other haematological parameters were investigated. The median HbF% of the cohort was 6.2
(inter-quartile range 3.42–9.70). The results of our genetic-association analysis are shown in
Table 2 and genotypic values for HbF and other haematological parameters are plotted in Figs
1 and 2.
BCL11A: The primary variant tagging this locus, rs1427407, was strongly associated with
HbF levels (β = 0.47, p = 7 x 10−10) and also showed a marked influence on anaemia: median
[Hb] was 8.2 g/dL for GG genotype patients, 8.6 g/dL for the GT genotype, and 8.9 g/dL for
the TT genotype [p = 0.011] (Fig 2). The influence of this marker is enhanced by the high prev-
alence of the HbF-increasing allele ‘T’ (23%), an allele frequency typical for African popula-
tions [24] and African patients with SCA [25]. As previously observed in African American
[13] and Tanzanian patients [25], a second association signal at BCL11A (rs6545816) was
detected when adjusting for the effect of the primary signal at rs1427407 (Table 3). Aligning
alleles at the two variants into haplotypes (Fig 3) reveals the genetic architecture underlying
this finding: the HbF-boosting allele (‘C’) for rs6545816 occurred solely on haplotypes/chro-
mosomes carrying the low-HbF allele for the primary marker, rs1427407. Investigating human
population data from the 1000 Genomes Project Phase III [24], we found that the HbF-boost-
ing alleles for both markers were exclusively in such a repulsion phase alignment in African
and Asian populations and that coupling phase (both high-HbF alleles united in cis) was
exceedingly rare (found in 3 out of 5,008 individuals) across all human populations studied.
Table 1. Presence and frequency of HbF-boosting genetic variants in Nigerian patients.
Locus Variants Position on chromosome Allele change Genotypes detected HbF-boosting allele (frequency)
Chromosome 2
BCL11A rs6545816 60,568,365 A > C AA, n = 97 C (35%)
AC, n = 116
CC, n = 27
rs1427407 60,571,547 G > T GG, n = 133 T (23%)
GT, n = 89
TT, n = 8
Chromosome 6
HMIP-2 rs9376090 135,452,920 T > C TT, n = 260 C (0%)
rs66650371 135,460,326-
135,460,328
In > Del II, n = 245
DI, n = 15
D (3%)
rs9402686 135,469,509 G > A GG, n = 244 A (3%)
GA, n = 14
AA, n = 1
rs6920211 135,473,011 T > C CC, n = 37 C (36%)
TC, n = 113
TT, n = 109
Chromosome11
Xmn1-HBG2 rs7482144 5,232,745 G > A GG, n = 247 A (2%)
GA, n = 8
AA, n = 1
 While this variant has been found associated with HbF in other populations, we have not detected this effect in our patients.
https://doi.org/10.1371/journal.pone.0197927.t001
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HBS1L-MYB: Both known main HbF sub-loci in this region, HMIP-2A (tagged by
rs66650371) [16, 27] and HMIP-2B (tagged by rs9402686) [13, 16, 26] were significantly (p =
0.002 and p = 1.23 x 10−4, respectively) associated with HbF%, with similar allelic effects (β ~
0.6). The 3-bp deleted allele of rs66650371was also associated with increased haemoglobin lev-
els. It was the only variant studied that had a significant effect on the red blood cell count. This
marker was also strongly associated with lower platelet counts (Table 2, Fig 2). HbF-increasing
alleles at HBS1L-MYB had low frequencies (3%), as is characteristic for African populations.
Similar to the BCL11A locus, HbF-increasing alleles at the two sub-loci occurred within differ-
ent haplotypes (Fig 2), which is typical for individuals of African descent [13, 16, 26]. This
stands in contrast to the situation in European populations, where HbF-increasing alleles usu-
ally appear to be combined into a single haplotype (HMIP-2AB) [16]. Accordingly, for an
ancestry informative marker tagging this haplotype, rs9376090, we did not detect the ‘G’ allele,
indicating the absence of HMIP-2AB haplotypes and suggesting a lack of European, Asian, or
North African admixture in our patient cohort [16, 24, 26]. Of all variants studied, rs9402686
had the largest allelic effect on HbF levels [β = 0.631, p = 1.23 x 10−4], resulting in median HbF
values of 5.75% for the GG genotype and 13.8% for the GA genotype (the single person with
AA genotype had an HbF of 4.2%) (Fig 1).
XmnI-HBG2 (rs7482144): As it is typical for African populations, the rs7482144 ‘A’ allele
that is associated with boosting HbF is infrequent (2%) among our patients. While a strong
effect for this variant was seen in Tanzanian patients [15], we detected no association with
HbF or general haematological parameters, most likely due to the small number of our patients
that carry the ‘A’ allele, resulting in a lack of statistical power.
HbF levels correlated positively with total haemoglobin [β = 0.05, p = 7.75 x 10−5] and
MCV [β = 4.87, p = 6.70 x 10−7] but negatively with WBC [β = -0.093, p = 0.001] and platelet
counts [β = -0.08, p = 0.047].
Discussion
In our survey of an initial group of 260 Nigerian patients with sickle cell anaemia, we have
detected the effect of two known QTL for the expression of fetal haemoglobin, BCL11A and
Table 2. Effect of fetal haemoglobin itself and of the genetic HbF modifier variants studied on haematological outcome variables.
Variables
Hb F (ln HbF%) rs6545816 rs1427407 rs66650371 rs9402686 rs6920211
(P-value)
rs7482144
(P-value)
In HbF% —— − 0.013 (0.851) 0.474 (7.04x 10−10) 0.577 (0.002) 0.631 (1.23 x 10−4) 0.147 (0.017) 0.200 (0.326)
In Hb 0.05 (7.75 x 10−5) 0.01 (0.387) 0.05 (0.004) 0.14 (0.001) 0.02 (0.548) 0.002 (0.905) 0.032 (0.715)
In WBC -0.093 (0.001) 0.06 (0.057) -0.05 (0.168) 0.01 (0.906) -0.12 (0.115) 0.02 (0.458) 0.010 (0.820)
In RBC -0.0001 (0.997) 0.144 (0.508) 0.03 (0.284) 0.18 (3.15 x 10−4) -0.02 (0.626) -0.01 (0.713) 0.01 (0.931)
In PLT -0.08 (0.047) 0.131 (0.003) -0.122 (0.020) -0.434 (2.08 x 10−4) -0.15 (0.144) -0.05 (0.229) -0.09 (0.484)
MCV 4.87 (6.70 x 10−7) -0.47 (0.584) 1.89 (0.064) -2.86 (0.212) 4.502 (0.031) 0.79 (0.306) 0.44 (0.862)
In MCH 0.02 (0.191) 0.01 (0.746) 0.01 (0.615) -0.06 (0.253) 0.04 (0.431) 0.03 (0.071) 0.01 (0.933)
MCHC -0.19 (0.133) 0.12 (0.412) 0.15 (0.374) -0.50 (0.187) -0.30 (0.389) -0.06 (0.634) 0.20 (0.628)
ln Abs. Lymphocytes -0.097 (0.004) -0.06 (0.121) -0.07 (0.119) -0.15 (0.139) -0.05 (0.557) 0.02 (0.560) -0.08 (0.468)
ln Abs. Neutrophils -0.12 (0.001) 0.06 (0.147) -0.06 (0.271) -0.096 (0.387) -0.13 (0.184) -0.03 (0.386) 0.12 (0.324)
Reticulocytes -0.35 (0.316) -0.03 (0.934) -0.979 (0.033) -0.34 (0.740) 0.002 (0.998) 0.13 (0.694) -1.07 (0.456)
Linear multiple regression included sex and age as covariates. Allelic effects are presented as regression coefficient (β, p-values in brackets). Bold font indicates statistical
significance.
https://doi.org/10.1371/journal.pone.0197927.t002
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HMIP, but not for the third, Xmn1-HBG2. HbF-inducing variants at the former two loci
showed beneficial effects on sickle cell pathology, as seen through an improvement of anaemia
and other haematological variables.
Our genetic findings have identified starting points for identifying further functional DNA
segments and biological mechanisms involved in the regulation of HbF expression. At
HBS1L-MYB, the small deletion rs66650371, residing within the HMIP-2A sub-locus, is already
well characterized and is likely of direct functional significance [27, 28] for critical regulatory
elements within the core enhancer for MYB, which encodes an important erythroid transcrip-
tion factor [29]. The strong association signal we obtained at the second sub-locus [13, 16],
HMIP-2B (rs9402686), is providing an opening for the discovery of a novel functional site reg-
ulating HbF levels. At BCL11A, the primary associated variant rs1427407 [5, 6, 14, 17] has been
shown to disrupt a critical element (‘-58’) at the erythroid enhancer for this gene [30], which
encodes a transcriptional repressor of γ globin gene (i.e., HbF) expression. The presence of the
Fig 1. Genotypic values for HbF levels at the three main QTL. Boxes show the inter-quartile range; the line denotes
the median. Whiskers indicate the full range of values observed. P-values are shown in Table 2.
https://doi.org/10.1371/journal.pone.0197927.g001
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Fig 2. Variants with significant (p < 0.005) impact on haematological variables in our patients. Boxes show the
inter-quartile range; the line denotes the median. Whiskers indicate the full range of values observed. Individual p-
values are shown in Table 2.
https://doi.org/10.1371/journal.pone.0197927.g002
Table 3. Joint analysis of the BCL11A variants rs6545816 and rs1427407.
Variables
rs6545816
(conditioned on rs1427407)
rs1427407
(conditioned on rs6545816)
In Hb F% 0.16(0.022) 0.55 (6.0 x 10−11)
In Hb 0.03 (0.093) 0.07 (0.001)
In WBC 0.05 (0.177) -0.03 (0.478)
In RBC 0.02 (0.468) 0.03 (0.203)
In PLT 0.12 (0.015) -0.07 (0.25)
MCV 0.14 (0.889) 1.96 (0.081)
In MCH 0.01 (0.529) 0.02 (0.474)
MCHC 0.27 (0.095) 0.28 (0.134)
ln Abs. Lymphocytes -0.05 (0.333) 0.05 (0.262)
ln Abs. Neutrophils 0.04 (0.390) -0.04 (0.514)
Reticulocytes -0.17 (0.697) -1.05 (0.035)
https://doi.org/10.1371/journal.pone.0197927.t003
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previously described secondary association signal (rs6545816) [13, 25] in Nigerian patients will
help to uncover other HbF-raising alleles or regulatory elements affecting HbF levels through
the BCL11Amechanism. Our observation that, at both loci, HbF-raising variants do not exist
in cis in our patients (Fig 3) and in African populations in general could mean either that they
are allelic, i.e. mutually-exclusive on the physical level of DNA sequence, or that natural selec-
tion has disfavoured a situation where two HbF-raising variants affect the same copy of either
gene.
In our patients, we detected no effect of the Gγ chain promoter polymorphism Xmn1-HBG2
on HbF levels or other haematological parameters, in contrast to what has been reported for
patients from US, Tanzania, the UK and Brazil [14, 15, 18], but in agreement with findings
from another West African country, Cameroon [18]. Nigerian patients have been found previ-
ously to lack [31, 32] HbF-increasing β globin gene locus haplotypes containing the
‘Xmn1-HBG2 A’ allele (‘Arab-Indian’ and ‘Senegal’ haplotypes). Accordingly, the small num-
ber of our patients (n = 5) carrying the HbF-boosting ‘A’ allele (called Xmn1’+’ in older papers)
has not allowed us to evaluate its effect. Other active components of the ‘Senegal’ and ‘Arab-
Indian’ haplotypes have been proposed [13] and might have a more important role in Nigerian
patients.
Beneficial effects of elevated HbF seen in our study (reduced anaemia, leucocytosis, and
thrombocytosis) are partially explained by the genetic variants investigated here. However as
observed before [14, 33] [34], the relationship between common genetic variation, HbF levels
and disease phenotype is not straightforward and to unravel their mutual dependence will
require a systematic dissection in large collaborative studies.
Conclusion
The present study demonstrated the presence and beneficial effects of two quantitative-trait
loci for fetal haemoglobin expression, BCL11A and HMIP, and the likely absence of a third,
Xmn1-HBG2, in Nigerian patients with SCA. Our results make a case for the development of
further, extended studies in Nigeria, as presently planned by us and others. Ideally, these will
include genome-wide association testing to discover novel disease modifier loci. Up to now,
most research on sickle cell disease has taken place in the US and Europe while the great
majority of patients live in Africa. Genetic and epidemiological studies can help to address this
imbalance.
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Fig 3. Haplotypes of genetic variants detected at the BCL11A and HMIP loci. Red letters denote HbF-increasing
alleles. HMIP haplotypes were named to match the locus architecture described previously [16, 26]. A situation with
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